APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologics and Biosimilars

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.

Selected research

Market Analysis & Forecast

Global Biologics and Biosimilars Market Analysis and Forecast 2026-2032

25 December 2025200 pages

Choose your research edition.

Industry ResearchBiologics and Biosimilars Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics and Biosimilars Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics and Biosimilars Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics and Biosimilars Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.

The major global manufacturers of biologics and biosimilars are Roche, Amgen, AbbVie, Sanofi-Aventis, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, Sansheng Pharmaceuticals, Changchun Gaoxin, CITICS Guojia, Baitai Biotech, Sijin Biotech, Cinda Biotech, Tonghua Dongbao, Ganli and Union Pharmaceuticals, etc. Roche, Amgen and AbbVie are the top three, with a combined market share of about 37%.

Read the full market overview

This report presents an overview of global market for Biologics and Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Biologics and Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Biologics and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biologics and Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Biologics and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Biologics and Biosimilars sales, projected growth trends, production technology, application and end-user industry.

Biologics and Biosimilars Segment by Company

Roche

Amgen

AbbVie

Sanofi-Aventis

Johnson & Johnson

Pfizer

Novo Nordisk

Eli Lilly

Novartis

Merck

3sbio

Changchun High Tech

CP Guojian

Biotech

Gelgen

Innovent

Dong Bao

Ganlee

United Laboratories

Biologics and Biosimilars Segment by Type

Monoclonal Antibodies

Interferon

Erythropoietin

Insulin

Vaccines

Others

Biologics and Biosimilars Segment by Application

Tumor

Diabetes

Cardiovascular

Hemophilia

Others

Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Biologics and Biosimilars in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Biologics and Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biologics and Biosimilars sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Monoclonal Antibodies Major Manufacturers Table 3. Interferon Major Manufacturers Table 4. Erythropoietin Major Manufacturers Table 5. Insulin Major Manufacturers Table 6. Vaccines Major Manufacturers Table 7. Others Major Manufacturers Table 8. Global Biologics and Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Tumor Major Manufacturers Table 10. Diabetes Major Manufacturers Table 11. Cardiovascular Major Manufacturers Table 12. Hemophilia Major Manufacturers Table 13. Others Major Manufacturers Table 14. Biologics and Biosimilars Industry Trends Table 15. Biologics and Biosimilars Industry Drivers Table 16. Biologics and Biosimilars Industry Opportunities and Challenges Table 17. Biologics and Biosimilars Industry Restraints Table 18. Global Biologics and Biosimilars Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Biologics and Biosimilars Revenue by Region (2021-2026) & (US$ Million) Table 20. Global Biologics and Biosimilars Revenue by Region (2027-2032) & (US$ Million) Table 21. Global Biologics and Biosimilars Revenue Market Share by Region (2021-2026) Table 22. Global Biologics and Biosimilars Revenue Market Share by Region (2027-2032) Table 23. Global Biologics and Biosimilars Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 24. Global Biologics and Biosimilars Sales by Region (2021-2026) & (K Units) Table 25. Global Biologics and Biosimilars Sales by Region (2027-2032) & (K Units) Table 26. Global Biologics and Biosimilars Sales Market Share by Region (2021-2026) Table 27. Global Biologics and Biosimilars Sales Market Share by Region (2027-2032) Table 28. Global Biologics and Biosimilars Revenue by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Biologics and Biosimilars Revenue Market Share by Manufacturers (2021-2026) Table 30. Global Biologics and Biosimilars Sales by Manufacturers (US$ Million) & (2021-2026) Table 31. Global Biologics and Biosimilars Sales Market Share by Manufacturers (2021-2026) Table 32. Global Biologics and Biosimilars Sales Price (USD/Unit) of Manufacturers (2021-2026) Table 33. Global Biologics and Biosimilars Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 34. Global Biologics and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters Table 35. Global Biologics and Biosimilars Manufacturers, Product Type & Application Table 36. Global Biologics and Biosimilars Manufacturers' Establishment Date Table 37. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 38. Global Biologics and Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Biologics and Biosimilars Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 41. Global Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 42. Global Biologics and Biosimilars Revenue Market Share by Type (2021-2026) Table 43. Global Biologics and Biosimilars Revenue Market Share by Type (2027-2032) Table 44. Global Biologics and Biosimilars Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 45. Global Biologics and Biosimilars Sales by Type (2021-2026) & (K Units) Table 46. Global Biologics and Biosimilars Sales by Type (2027-2032) & (K Units) Table 47. Global Biologics and Biosimilars Sales Market Share by Type (2021-2026) Table 48. Global Biologics and Biosimilars Sales Market Share by Type (2027-2032) Table 49. Global Biologics and Biosimilars Price by Type (2021-2026) & (USD/Unit) Table 50. Global Biologics and Biosimilars Price by Type (2027-2032) & (USD/Unit) Table 51. Global Biologics and Biosimilars Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 53. Global Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 54. Global Biologics and Biosimilars Revenue Market Share by Application (2021-2026) Table 55. Global Biologics and Biosimilars Revenue Market Share by Application (2027-2032) Table 56. Global Biologics and Biosimilars Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 57. Global Biologics and Biosimilars Sales by Application (2021-2026) & (K Units) Table 58. Global Biologics and Biosimilars Sales by Application (2027-2032) & (K Units) Table 59. Global Biologics and Biosimilars Sales Market Share by Application (2021-2026) Table 60. Global Biologics and Biosimilars Sales Market Share by Application (2027-2032) Table 61. Global Biologics and Biosimilars Price by Application (2021-2026) & (USD/Unit) Table 62. Global Biologics and Biosimilars Price by Application (2027-2032) & (USD/Unit) Table 63. Roche Company Information Table 64. Roche Business Overview Table 65. Roche Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 66. Roche Biologics and Biosimilars Product Portfolio Table 67. Roche Recent Development Table 68. Amgen Company Information Table 69. Amgen Business Overview Table 70. Amgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 71. Amgen Biologics and Biosimilars Product Portfolio Table 72. Amgen Recent Development Table 73. AbbVie Company Information Table 74. AbbVie Business Overview Table 75. AbbVie Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 76. AbbVie Biologics and Biosimilars Product Portfolio Table 77. AbbVie Recent Development Table 78. Sanofi-Aventis Company Information Table 79. Sanofi-Aventis Business Overview Table 80. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 81. Sanofi-Aventis Biologics and Biosimilars Product Portfolio Table 82. Sanofi-Aventis Recent Development Table 83. Johnson & Johnson Company Information Table 84. Johnson & Johnson Business Overview Table 85. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 86. Johnson & Johnson Biologics and Biosimilars Product Portfolio Table 87. Johnson & Johnson Recent Development Table 88. Pfizer Company Information Table 89. Pfizer Business Overview Table 90. Pfizer Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 91. Pfizer Biologics and Biosimilars Product Portfolio Table 92. Pfizer Recent Development Table 93. Novo Nordisk Company Information Table 94. Novo Nordisk Business Overview Table 95. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 96. Novo Nordisk Biologics and Biosimilars Product Portfolio Table 97. Novo Nordisk Recent Development Table 98. Eli Lilly Company Information Table 99. Eli Lilly Business Overview Table 100. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 101. Eli Lilly Biologics and Biosimilars Product Portfolio Table 102. Eli Lilly Recent Development Table 103. Novartis Company Information Table 104. Novartis Business Overview Table 105. Novartis Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 106. Novartis Biologics and Biosimilars Product Portfolio Table 107. Novartis Recent Development Table 108. Merck Company Information Table 109. Merck Business Overview Table 110. Merck Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 111. Merck Biologics and Biosimilars Product Portfolio Table 112. Merck Recent Development Table 113. 3sbio Company Information Table 114. 3sbio Business Overview Table 115. 3sbio Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 116. 3sbio Biologics and Biosimilars Product Portfolio Table 117. 3sbio Recent Development Table 118. Changchun High Tech Company Information Table 119. Changchun High Tech Business Overview Table 120. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 121. Changchun High Tech Biologics and Biosimilars Product Portfolio Table 122. Changchun High Tech Recent Development Table 123. CP Guojian Company Information Table 124. CP Guojian Business Overview Table 125. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 126. CP Guojian Biologics and Biosimilars Product Portfolio Table 127. CP Guojian Recent Development Table 128. Biotech Company Information Table 129. Biotech Business Overview Table 130. Biotech Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 131. Biotech Biologics and Biosimilars Product Portfolio Table 132. Biotech Recent Development Table 133. Gelgen Company Information Table 134. Gelgen Business Overview Table 135. Gelgen Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 136. Gelgen Biologics and Biosimilars Product Portfolio Table 137. Gelgen Recent Development Table 138. Innovent Company Information Table 139. Innovent Business Overview Table 140. Innovent Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 141. Innovent Biologics and Biosimilars Product Portfolio Table 142. Innovent Recent Development Table 143. Dong Bao Company Information Table 144. Dong Bao Business Overview Table 145. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 146. Dong Bao Biologics and Biosimilars Product Portfolio Table 147. Dong Bao Recent Development Table 148. Ganlee Company Information Table 149. Ganlee Business Overview Table 150. Ganlee Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 151. Ganlee Biologics and Biosimilars Product Portfolio Table 152. Ganlee Recent Development Table 153. United Laboratories Company Information Table 154. United Laboratories Business Overview Table 155. United Laboratories Biologics and Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 156. United Laboratories Biologics and Biosimilars Product Portfolio Table 157. United Laboratories Recent Development Table 158. North America Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 159. North America Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 160. North America Biologics and Biosimilars Sales by Type (2021-2026) & (K Units) Table 161. North America Biologics and Biosimilars Sales by Type (2027-2032) & (K Units) Table 162. North America Biologics and Biosimilars Sales Price by Type (2021-2026) & (USD/Unit) Table 163. North America Biologics and Biosimilars Sales Price by Type (2027-2032) & (USD/Unit) Table 164. North America Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 165. North America Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 166. North America Biologics and Biosimilars Sales by Application (2021-2026) & (K Units) Table 167. North America Biologics and Biosimilars Sales by Application (2027-2032) & (K Units) Table 168. North America Biologics and Biosimilars Sales Price by Application (2021-2026) & (USD/Unit) Table 169. North America Biologics and Biosimilars Sales Price by Application (2027-2032) & (USD/Unit) Table 170. North America Biologics and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 171. North America Biologics and Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 172. North America Biologics and Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 173. North America Biologics and Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 174. North America Biologics and Biosimilars Sales by Country (2021-2026) & (K Units) Table 175. North America Biologics and Biosimilars Sales by Country (2027-2032) & (K Units) Table 176. North America Biologics and Biosimilars Sales Price by Country (2021-2026) & (USD/Unit) Table 177. North America Biologics and Biosimilars Sales Price by Country (2027-2032) & (USD/Unit) Table 178. United States Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 179. Canada Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 180. Mexico Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 181. Europe Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 182. Europe Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 183. Europe Biologics and Biosimilars Sales by Type (2021-2026) & (K Units) Table 184. Europe Biologics and Biosimilars Sales by Type (2027-2032) & (K Units) Table 185. Europe Biologics and Biosimilars Sales Price by Type (2021-2026) & (USD/Unit) Table 186. Europe Biologics and Biosimilars Sales Price by Type (2027-2032) & (USD/Unit) Table 187. Europe Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 188. Europe Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 189. Europe Biologics and Biosimilars Sales by Application (2021-2026) & (K Units) Table 190. Europe Biologics and Biosimilars Sales by Application (2027-2032) & (K Units) Table 191. Europe Biologics and Biosimilars Sales Price by Application (2021-2026) & (USD/Unit) Table 192. Europe Biologics and Biosimilars Sales Price by Application (2027-2032) & (USD/Unit) Table 193. Europe Biologics and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 194. Europe Biologics and Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 195. Europe Biologics and Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 196. Europe Biologics and Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 197. Europe Biologics and Biosimilars Sales by Country (2021-2026) & (K Units) Table 198. Europe Biologics and Biosimilars Sales by Country (2027-2032) & (K Units) Table 199. Europe Biologics and Biosimilars Sales Price by Country (2021-2026) & (USD/Unit) Table 200. Europe Biologics and Biosimilars Sales Price by Country (2027-2032) & (USD/Unit) Table 201. Germany Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 202. France Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 203. U.K. Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 204. Italy Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 205. Russia Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 206. Spain Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 207. Netherlands Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 208. Switzerland Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 209. Sweden Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 210. Poland Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 211. China Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 212. China Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 213. China Biologics and Biosimilars Sales by Type (2021-2026) & (K Units) Table 214. China Biologics and Biosimilars Sales by Type (2027-2032) & (K Units) Table 215. China Biologics and Biosimilars Sales Price by Type (2021-2026) & (USD/Unit) Table 216. China Biologics and Biosimilars Sales Price by Type (2027-2032) & (USD/Unit) Table 217. China Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 218. China Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 219. China Biologics and Biosimilars Sales by Application (2021-2026) & (K Units) Table 220. China Biologics and Biosimilars Sales by Application (2027-2032) & (K Units) Table 221. China Biologics and Biosimilars Sales Price by Application (2021-2026) & (USD/Unit) Table 222. China Biologics and Biosimilars Sales Price by Application (2027-2032) & (USD/Unit) Table 223. Asia Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 224. Asia Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 225. Asia Biologics and Biosimilars Sales by Type (2021-2026) & (K Units) Table 226. Asia Biologics and Biosimilars Sales by Type (2027-2032) & (K Units) Table 227. Asia Biologics and Biosimilars Sales Price by Type (2021-2026) & (USD/Unit) Table 228. Asia Biologics and Biosimilars Sales Price by Type (2027-2032) & (USD/Unit) Table 229. Asia Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 230. Asia Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 231. Asia Biologics and Biosimilars Sales by Application (2021-2026) & (K Units) Table 232. Asia Biologics and Biosimilars Sales by Application (2027-2032) & (K Units) Table 233. Asia Biologics and Biosimilars Sales Price by Application (2021-2026) & (USD/Unit) Table 234. Asia Biologics and Biosimilars Sales Price by Application (2027-2032) & (USD/Unit) Table 235. Asia Biologics and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 236. Asia Biologics and Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 237. Asia Biologics and Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 238. Asia Biologics and Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 239. Asia Biologics and Biosimilars Sales by Country (2021-2026) & (K Units) Table 240. Asia Biologics and Biosimilars Sales by Country (2027-2032) & (K Units) Table 241. Asia Biologics and Biosimilars Sales Price by Country (2021-2026) & (USD/Unit) Table 242. Asia Biologics and Biosimilars Sales Price by Country (2027-2032) & (USD/Unit) Table 243. Japan Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 244. South Korea Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 245. India Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 246. Australia Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 247. Taiwan Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 248. Southeast Asia Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 249. SAMEA Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 250. SAMEA Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 251. SAMEA Biologics and Biosimilars Sales by Type (2021-2026) & (K Units) Table 252. SAMEA Biologics and Biosimilars Sales by Type (2027-2032) & (K Units) Table 253. SAMEA Biologics and Biosimilars Sales Price by Type (2021-2026) & (USD/Unit) Table 254. SAMEA Biologics and Biosimilars Sales Price by Type (2027-2032) & (USD/Unit) Table 255. SAMEA Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 256. SAMEA Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 257. SAMEA Biologics and Biosimilars Sales by Application (2021-2026) & (K Units) Table 258. SAMEA Biologics and Biosimilars Sales by Application (2027-2032) & (K Units) Table 259. SAMEA Biologics and Biosimilars Sales Price by Application (2021-2026) & (USD/Unit) Table 260. SAMEA Biologics and Biosimilars Sales Price by Application (2027-2032) & (USD/Unit) Table 261. SAMEA Biologics and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 262. SAMEA Biologics and Biosimilars Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 263. SAMEA Biologics and Biosimilars Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 264. SAMEA Biologics and Biosimilars Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 265. SAMEA Biologics and Biosimilars Sales by Country (2021-2026) & (K Units) Table 266. SAMEA Biologics and Biosimilars Sales by Country (2027-2032) & (K Units) Table 267. SAMEA Biologics and Biosimilars Sales Price by Country (2021-2026) & (USD/Unit) Table 268. SAMEA Biologics and Biosimilars Sales Price by Country (2027-2032) & (USD/Unit) Table 269. Brazil Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 270. Argentina Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 271. Chile Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 272. Colombia Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 273. Peru Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 274. Saudi Arabia Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 275. Israel Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 276. UAE Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 277. Turkey Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 278. Iran Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 279. Egypt Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Table 280. Key Raw Materials Table 281. Raw Materials Key Suppliers Table 282. Biologics and Biosimilars Distributors List Table 283. Biologics and Biosimilars Customers List Table 284. Research Programs/Design for This Report Table 285. Authors List of This Report Table 286. Secondary Sources Table 287. Primary Sources List of Figures Figure 1. Biologics and Biosimilars Image Figure 2. Global Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologics and Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 4. Monoclonal Antibodies Image Figure 5. Interferon Image Figure 6. Erythropoietin Image Figure 7. Insulin Image Figure 8. Vaccines Image Figure 9. Others Image Figure 10. Global Biologics and Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Biologics and Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 12. Tumor Image Figure 13. Diabetes Image Figure 14. Cardiovascular Image Figure 15. Hemophilia Image Figure 16. Others Image Figure 17. Global Biologics and Biosimilars Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Biologics and Biosimilars Revenue (2021-2032) & (US$ Million) Figure 19. Global Biologics and Biosimilars Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Biologics and Biosimilars Revenue Market Share by Region: 2025 Versus 2032 Figure 21. Global Biologics and Biosimilars Revenue Market Share by Region (2021-2032) Figure 22. Global Biologics and Biosimilars Sales (2021-2032) & (K Units) Figure 23. Global Biologics and Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 24. Global Biologics and Biosimilars Sales Market Share by Region (2021-2032) Figure 25. US & Canada & Mexico Biologics and Biosimilars Sales YoY (2021-2032) & (K Units) Figure 26. Europe Biologics and Biosimilars Sales YoY (2021-2032) & (K Units) Figure 27. China Biologics and Biosimilars Sales YoY (2021-2032) & (K Units) Figure 28. Asia (Excluding China) Biologics and Biosimilars Sales YoY (2021-2032) & (K Units) Figure 29. South America, Middle East and Africa Biologics and Biosimilars Sales YoY (2021-2032) & (K Units) Figure 30. Global Biologics and Biosimilars Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 31. Global Biologics and Biosimilars Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 32. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Global Biologics and Biosimilars Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Biologics and Biosimilars Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Biologics and Biosimilars Revenue Market Share by Type (2021-2032) Figure 36. Global Biologics and Biosimilars Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Biologics and Biosimilars Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 38. Global Biologics and Biosimilars Sales Market Share by Type (2021-2032) Figure 39. Global Biologics and Biosimilars Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 40. Global Biologics and Biosimilars Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Biologics and Biosimilars Revenue Market Share by Application (2021-2032) Figure 42. Global Biologics and Biosimilars Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 43. Global Biologics and Biosimilars Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 44. Global Biologics and Biosimilars Sales Market Share by Application (2021-2032) Figure 45. North America Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 46. North America Biologics and Biosimilars Sales Share by Type (2021-2032) Figure 47. North America Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 48. North America Biologics and Biosimilars Sales Share by Application (2021-2032) Figure 49. North America Biologics and Biosimilars Revenue Share by Country (2021-2032) Figure 50. North America Biologics and Biosimilars Sales Share by Country (2021-2032) Figure 51. Europe Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 52. Europe Biologics and Biosimilars Sales Share by Type (2021-2032) Figure 53. Europe Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 54. Europe Biologics and Biosimilars Sales Share by Application (2021-2032) Figure 55. Europe Biologics and Biosimilars Revenue Share by Country (2021-2032) Figure 56. Europe Biologics and Biosimilars Sales Share by Country (2021-2032) Figure 57. China Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 58. China Biologics and Biosimilars Sales Share by Type (2021-2032) Figure 59. China Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 60. China Biologics and Biosimilars Sales Share by Application (2021-2032) Figure 61. Asia Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 62. Asia Biologics and Biosimilars Sales Share by Type (2021-2032) Figure 63. Asia Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 64. Asia Biologics and Biosimilars Sales Share by Application (2021-2032) Figure 65. Asia Biologics and Biosimilars Revenue Share by Country (2021-2032) Figure 66. Asia Biologics and Biosimilars Sales Share by Country (2021-2032) Figure 67. SAMEA Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 68. SAMEA Biologics and Biosimilars Sales Share by Type (2021-2032) Figure 69. SAMEA Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 70. SAMEA Biologics and Biosimilars Sales Share by Application (2021-2032) Figure 71. SAMEA Biologics and Biosimilars Revenue Share by Country (2021-2032) Figure 72. SAMEA Biologics and Biosimilars Sales Share by Country (2021-2032) Figure 73. Biologics and Biosimilars Value Chain Figure 74. Manufacturing Cost Structure Figure 75. Biologics and Biosimilars Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Years Considered Figure 79. Research Process Figure 80. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibodies
  • Interferon
  • Erythropoietin
  • Insulin
  • Vaccines
  • Others
Applications
  • Tumor
  • Diabetes
  • Cardiovascular
  • Hemophilia
  • Others
Companies covered
  • Roche
  • Amgen
  • AbbVie
  • Sanofi-Aventis
  • Johnson & Johnson
  • Pfizer
  • Novo Nordisk
  • Eli Lilly
  • Novartis
  • Merck
  • 3sbio
  • Changchun High Tech
  • CP Guojian
  • Biotech
  • Gelgen
  • Innovent
  • Dong Bao
  • Ganlee
  • United Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Biologics and Biosimilars Market by Type
  3. 1.2.1 Global Biologics and Biosimilars Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Monoclonal Antibodies
  5. 1.2.3 Interferon
  6. 1.2.4 Erythropoietin
  7. 1.2.5 Insulin
  8. 1.2.6 Vaccines
  9. 1.2.7 Others
  10. 1.3 Biologics and Biosimilars Market by Application
  11. 1.3.1 Global Biologics and Biosimilars Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Tumor
  13. 1.3.3 Diabetes
  14. 1.3.4 Cardiovascular
  15. 1.3.5 Hemophilia
  16. 1.3.6 Others
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Biologics and Biosimilars Market Dynamics
  1. 2.1 Biologics and Biosimilars Industry Trends
  2. 2.2 Biologics and Biosimilars Industry Drivers
  3. 2.3 Biologics and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Biologics and Biosimilars Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Biologics and Biosimilars Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Biologics and Biosimilars Revenue by Region
  3. 3.2.1 Global Biologics and Biosimilars Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Biologics and Biosimilars Revenue by Region (2021-2026)
  5. 3.2.3 Global Biologics and Biosimilars Revenue by Region (2027-2032)
  6. 3.2.4 Global Biologics and Biosimilars Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Biologics and Biosimilars Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Biologics and Biosimilars Sales by Region
  9. 3.4.1 Global Biologics and Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Biologics and Biosimilars Sales by Region (2021-2026)
  11. 3.4.3 Global Biologics and Biosimilars Sales by Region (2027-2032)
  12. 3.4.4 Global Biologics and Biosimilars Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Biologics and Biosimilars Revenue by Manufacturers
  2. 4.1.1 Global Biologics and Biosimilars Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Biologics and Biosimilars Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Biologics and Biosimilars Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Biologics and Biosimilars Sales by Manufacturers
  6. 4.2.1 Global Biologics and Biosimilars Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Biologics and Biosimilars Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Biologics and Biosimilars Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Biologics and Biosimilars Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Biologics and Biosimilars Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Biologics and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Biologics and Biosimilars Manufacturers, Product Type & Application
  13. 4.7 Global Biologics and Biosimilars Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Biologics and Biosimilars Market CR5 and HHI
  16. 4.8.2 2025 Biologics and Biosimilars Tier 1, Tier 2, and Tier 3
5 Biologics and Biosimilars Market by Type
  1. 5.1 Global Biologics and Biosimilars Revenue by Type
  2. 5.1.1 Global Biologics and Biosimilars Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Biologics and Biosimilars Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Biologics and Biosimilars Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Biologics and Biosimilars Sales by Type
  6. 5.2.1 Global Biologics and Biosimilars Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biologics and Biosimilars Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Biologics and Biosimilars Sales Market Share by Type (2021-2032)
  9. 5.3 Global Biologics and Biosimilars Price by Type
6 Biologics and Biosimilars Market by Application
  1. 6.1 Global Biologics and Biosimilars Revenue by Application
  2. 6.1.1 Global Biologics and Biosimilars Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Biologics and Biosimilars Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Biologics and Biosimilars Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Biologics and Biosimilars Sales by Application
  6. 6.2.1 Global Biologics and Biosimilars Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Biologics and Biosimilars Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Biologics and Biosimilars Sales Market Share by Application (2021-2032)
  9. 6.3 Global Biologics and Biosimilars Price by Application
7 Company Profiles
  1. 7.1 Roche
  2. 7.1.1 Roche Company Information
  3. 7.1.2 Roche Business Overview
  4. 7.1.3 Roche Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Roche Biologics and Biosimilars Product Portfolio
  6. 7.1.5 Roche Recent Developments
  7. 7.2 Amgen
  8. 7.2.1 Amgen Company Information
  9. 7.2.2 Amgen Business Overview
  10. 7.2.3 Amgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Amgen Biologics and Biosimilars Product Portfolio
  12. 7.2.5 Amgen Recent Developments
  13. 7.3 AbbVie
  14. 7.3.1 AbbVie Company Information
  15. 7.3.2 AbbVie Business Overview
  16. 7.3.3 AbbVie Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 AbbVie Biologics and Biosimilars Product Portfolio
  18. 7.3.5 AbbVie Recent Developments
  19. 7.4 Sanofi-Aventis
  20. 7.4.1 Sanofi-Aventis Company Information
  21. 7.4.2 Sanofi-Aventis Business Overview
  22. 7.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
  24. 7.4.5 Sanofi-Aventis Recent Developments
  25. 7.5 Johnson & Johnson
  26. 7.5.1 Johnson & Johnson Company Information
  27. 7.5.2 Johnson & Johnson Business Overview
  28. 7.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
  30. 7.5.5 Johnson & Johnson Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Biologics and Biosimilars Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 Novo Nordisk
  38. 7.7.1 Novo Nordisk Company Information
  39. 7.7.2 Novo Nordisk Business Overview
  40. 7.7.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
  42. 7.7.5 Novo Nordisk Recent Developments
  43. 7.8 Eli Lilly
  44. 7.8.1 Eli Lilly Company Information
  45. 7.8.2 Eli Lilly Business Overview
  46. 7.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
  48. 7.8.5 Eli Lilly Recent Developments
  49. 7.9 Novartis
  50. 7.9.1 Novartis Company Information
  51. 7.9.2 Novartis Business Overview
  52. 7.9.3 Novartis Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Novartis Biologics and Biosimilars Product Portfolio
  54. 7.9.5 Novartis Recent Developments
  55. 7.10 Merck
  56. 7.10.1 Merck Company Information
  57. 7.10.2 Merck Business Overview
  58. 7.10.3 Merck Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Merck Biologics and Biosimilars Product Portfolio
  60. 7.10.5 Merck Recent Developments
  61. 7.11 3sbio
  62. 7.11.1 3sbio Company Information
  63. 7.11.2 3sbio Business Overview
  64. 7.11.3 3sbio Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 3sbio Biologics and Biosimilars Product Portfolio
  66. 7.11.5 3sbio Recent Developments
  67. 7.12 Changchun High Tech
  68. 7.12.1 Changchun High Tech Company Information
  69. 7.12.2 Changchun High Tech Business Overview
  70. 7.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
  72. 7.12.5 Changchun High Tech Recent Developments
  73. 7.13 CP Guojian
  74. 7.13.1 CP Guojian Company Information
  75. 7.13.2 CP Guojian Business Overview
  76. 7.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
  78. 7.13.5 CP Guojian Recent Developments
  79. 7.14 Biotech
  80. 7.14.1 Biotech Company Information
  81. 7.14.2 Biotech Business Overview
  82. 7.14.3 Biotech Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Biotech Biologics and Biosimilars Product Portfolio
  84. 7.14.5 Biotech Recent Developments
  85. 7.15 Gelgen
  86. 7.15.1 Gelgen Company Information
  87. 7.15.2 Gelgen Business Overview
  88. 7.15.3 Gelgen Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Gelgen Biologics and Biosimilars Product Portfolio
  90. 7.15.5 Gelgen Recent Developments
  91. 7.16 Innovent
  92. 7.16.1 Innovent Company Information
  93. 7.16.2 Innovent Business Overview
  94. 7.16.3 Innovent Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Innovent Biologics and Biosimilars Product Portfolio
  96. 7.16.5 Innovent Recent Developments
  97. 7.17 Dong Bao
  98. 7.17.1 Dong Bao Company Information
  99. 7.17.2 Dong Bao Business Overview
  100. 7.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
  102. 7.17.5 Dong Bao Recent Developments
  103. 7.18 Ganlee
  104. 7.18.1 Ganlee Company Information
  105. 7.18.2 Ganlee Business Overview
  106. 7.18.3 Ganlee Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Ganlee Biologics and Biosimilars Product Portfolio
  108. 7.18.5 Ganlee Recent Developments
  109. 7.19 United Laboratories
  110. 7.19.1 United Laboratories Company Information
  111. 7.19.2 United Laboratories Business Overview
  112. 7.19.3 United Laboratories Biologics and Biosimilars Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
  114. 7.19.5 United Laboratories Recent Developments
8 North America
  1. 8.1 North America Biologics and Biosimilars Market Size by Type
  2. 8.1.1 North America Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 8.1.2 North America Biologics and Biosimilars Sales by Type (2021-2032)
  4. 8.1.3 North America Biologics and Biosimilars Price by Type (2021-2032)
  5. 8.2 North America Biologics and Biosimilars Market Size by Application
  6. 8.2.1 North America Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 8.2.2 North America Biologics and Biosimilars Sales by Application (2021-2032)
  8. 8.2.3 North America Biologics and Biosimilars Price by Application (2021-2032)
  9. 8.3 North America Biologics and Biosimilars Market Size by Country
  10. 8.3.1 North America Biologics and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Biologics and Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Biologics and Biosimilars Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Biologics and Biosimilars Market Size by Type
  2. 9.1.1 Europe Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 9.1.2 Europe Biologics and Biosimilars Sales by Type (2021-2032)
  4. 9.1.3 Europe Biologics and Biosimilars Price by Type (2021-2032)
  5. 9.2 Europe Biologics and Biosimilars Market Size by Application
  6. 9.2.1 Europe Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 9.2.2 Europe Biologics and Biosimilars Sales by Application (2021-2032)
  8. 9.2.3 Europe Biologics and Biosimilars Price by Application (2021-2032)
  9. 9.3 Europe Biologics and Biosimilars Market Size by Country
  10. 9.3.1 Europe Biologics and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Biologics and Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Biologics and Biosimilars Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Biologics and Biosimilars Market Size by Type
  2. 10.1.1 China Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 10.1.2 China Biologics and Biosimilars Sales by Type (2021-2032)
  4. 10.1.3 China Biologics and Biosimilars Price by Type (2021-2032)
  5. 10.2 China Biologics and Biosimilars Market Size by Application
  6. 10.2.1 China Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 10.2.2 China Biologics and Biosimilars Sales by Application (2021-2032)
  8. 10.2.3 China Biologics and Biosimilars Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Biologics and Biosimilars Market Size by Type
  2. 11.1.1 Asia Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 11.1.2 Asia Biologics and Biosimilars Sales by Type (2021-2032)
  4. 11.1.3 Asia Biologics and Biosimilars Price by Type (2021-2032)
  5. 11.2 Asia Biologics and Biosimilars Market Size by Application
  6. 11.2.1 Asia Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 11.2.2 Asia Biologics and Biosimilars Sales by Application (2021-2032)
  8. 11.2.3 Asia Biologics and Biosimilars Price by Application (2021-2032)
  9. 11.3 Asia Biologics and Biosimilars Market Size by Country
  10. 11.3.1 Asia Biologics and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Biologics and Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Biologics and Biosimilars Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Biologics and Biosimilars Market Size by Type
  2. 12.1.1 SAMEA Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Biologics and Biosimilars Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Biologics and Biosimilars Price by Type (2021-2032)
  5. 12.2 SAMEA Biologics and Biosimilars Market Size by Application
  6. 12.2.1 SAMEA Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Biologics and Biosimilars Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Biologics and Biosimilars Price by Application (2021-2032)
  9. 12.3 SAMEA Biologics and Biosimilars Market Size by Country
  10. 12.3.1 SAMEA Biologics and Biosimilars Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Biologics and Biosimilars Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Biologics and Biosimilars Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Biologics and Biosimilars Value Chain Analysis
  2. 13.1.1 Biologics and Biosimilars Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Biologics and Biosimilars Production Mode & Process
  6. 13.2 Biologics and Biosimilars Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Biologics and Biosimilars Distributors
  9. 13.2.3 Biologics and Biosimilars Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst